Business Context and Reporting Period
Company: Pyxis Oncology, Inc. (PYXS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Pyxis is a clinical-stage oncology company focused on developing antibody-drug conjugates (ADCs) for solid tumors, specifically head and neck squamous cell carcinoma (HNSCC). Its lead product candidate, micvotabart pelidotin (MICVO), targets the extracellular matrix component EDB+FN. The company has no approved products and has not generated revenue from product sales.
Key Financial Metrics
| Metric | 2025 (in millions) | 2024 (in millions) |
|---|---|---|
| Total Revenues | $13.9 | $16.1 |
| Net Loss | $(79.6) | $(77.3) |
| Research & Development Expenses | $73.7 | $58.7 |
| General & Administrative Expenses | $22.2 | $25.4 |
| Cash, Cash Equivalents, and Marketable Securities | $66.9 | $126.9 |
| Accumulated Deficit | $(443.2) | $(363.6) |
| Net Cash Used in Operating Activities | $(63.5) | $(57.7) |
Note: Revenues in 2025 were primarily driven by the sale of royalty rights ($11.0M) and a regulatory milestone ($2.8M) from the Simcere agreement. 2024 revenues included a settlement with Novartis ($8.0M) and royalty revenues ($8.1M).
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased by $2.3 million (14%) year-over-year, primarily due to the absence of royalty revenues from the Novartis settlement in 2025, partially offset by the sale of royalty rights to Simcere.
- Increased R&D Spend: R&D expenses increased by $15.0 million (25%), driven by a $14.1 million increase in MICVO program costs due to expanded clinical trials and manufacturing runs.
- Reduced G&A: General and administrative expenses decreased by $3.2 million (13%), attributed to lower personnel costs and reduced stock-based compensation.
- Impairment Reversal: The $21.0 million impairment of in-process R&D intangible assets recorded in 2024 (related to PYX-107) did not recur in 2025.
- Liquidity Position: Cash and marketable securities decreased by approximately $60 million, reflecting the net cash burn from operations and investment activities.
Guidance, Outlook, and Risks
Going Concern Warning
The company has stated that its current cash, cash equivalents, and marketable debt securities ($66.9 million as of Dec 31, 2025) are sufficient to fund operations only into the fourth quarter of 2026. This raises substantial doubt about the company's ability to continue as a going concern for one year from the date of the report. Additional capital will be required to fund clinical trials and operations.
Clinical Outlook
- MICVO Monotherapy: Phase 1 dose expansion in 2L+ R/M HNSCC is ongoing. Updated data is expected in mid-2026. The company is evaluating dose capping and adjusted ideal body weight (AIBW) dosing to improve tolerability in high body weight patients.
- MICVO Combination: Phase 1/2 study with Merck's KEYTRUDA (pembrolizumab) is ongoing. Updated data for 1L/2L+ R/M HNSCC is expected in the second half of 2026.
- Regulatory: MICVO holds Fast Track designation for R/M HNSCC. The company received FDA feedback on the design for a planned pivotal monotherapy study in Q4 2025.
Key Risks
- Capital Needs: Inability to raise additional capital could force delays or termination of clinical programs.
- Clinical Failure: MICVO is in early clinical stages; failure to demonstrate safety or efficacy in larger trials would materially harm the business.
- Manufacturing Dependence: Reliance on third-party manufacturers, including facilities in China, exposes the company to supply chain and geopolitical risks.
- Intellectual Property: Significant reliance on in-licensed technology from Pfizer and the University of Chicago.
Investor Verification Checklist
- Cash Runway: Verify the timeline for the next capital raise given the Q4 2026 liquidity horizon.
- MICVO Safety Data: Monitor upcoming mid-2026 data releases regarding the impact of dose capping/AIBW dosing on tolerability in high body weight patients.
- Revenue Sustainability: Confirm that 2025 revenues were non-recurring (royalty sales/milestones) and that no product revenue is expected in the near term.
- Manufacturing Supply Chain: Assess the company's contingency plans for third-party manufacturing, particularly regarding potential restrictions on Chinese biotechnology providers.
- License Obligations: Review milestone and royalty payment obligations under the Pfizer and University of Chicago agreements to understand future cash outflows upon commercialization.